Skip to main content

Lilly Asia Ventures — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

102
Companies
$7.7B
Total invested
$95.6M
Avg. check
14
Industries
Biotechnology 22Health Care 16Medical 12Pharmaceutical 11Therapeutics 9Life Science 7+8 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 124 of 102
Genesis Medtech
August 2024

Genesis Medtech is a medical device company.

Health Care · Singapore$25.0M Corporate Round
CinCor Pharma
August 2022

CinCor is a clinical-stage biopharmaceutical company that develops treatments for cardiovascular diseases.

Biotechnology · Cincinnati$225.0M Post-IPO Equity
Singlera Genomics
June 2022

Singlera Genomics is a fast growing company focusing on non-invasive genetic testing.

Biotechnology · La Jolla$44.9M Series B
Legend Biotech
June 2026

Legend Biotech is a biopharmaceutical company that develops and commercializes novel cell therapies for oncology.

Biotechnology · Piscataway$226.0M Post-IPO Equity
Tempest Therapeutics
May 2026

Tempest Therapeutics is a biotechnology company that focuses on small molecule therapeutics that modulate anti-tumor pathways.

Biotechnology · San Francisco$2.0M Post-IPO Equity
ArriVent
May 2026

ArriVent develops pharmaceutical products to cure presently untreatable cancer.

Biotechnology · Pennsylvania Furnace$250.0M Post-IPO Equity
Gritstone bio
April 2024

Gritstone bio is a biotechnology company that develops immunotherapies for cancer and infectious diseases.

Biotechnology · Emeryville$32.5M Post-IPO Equity
Inhibrx
March 2026

Inhibrx is a clinical-stage biotechnology company that focuses on developing a broad pipeline of biologic therapeutic candidates.

Biopharma · La Jolla$75.0M Post-IPO Debt
Excalipoint Therapetics
March 2026

Excalipoint Therapeutics develops targeted therapies that focus on modulating disease pathways at specific biological points.

Biotechnology · Admiralty$27.7M Seed
QuantX Biosciences
February 2026

QuantX Biosciences is a biotechnology company that specializes in computational drug discovery and small-molecule therapeutic products.

Biotechnology · Princeton$85.0M Series B
ADARx Pharmaceuticals
February 2025

ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts.

Biotechnology · San DiegoVenture - Series Unknown
Timberlyne Therapeutics
January 2025

Timberlyne Therapeutics is a biopharmaceutical company that develops therapies for autoimmune diseases.

Biopharma · San Diego$180.0M Series A
Comanche Biopharma
January 2024

Our purpose is to make every pregnancy around the world safer.

Biopharma · Concord$75.0M Series B
Synnovation Therapeutics
December 2023

Synnovation Therapeutics is a precision oncology company that develops therapeutics that aims to help people with cancer.

Biotechnology · Wilmington$102.0M Series A
Rgenta Therapeutics
May 2023

Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology.

Biotechnology · Cambridge$8.0M Series A
Verdiva Bio
January 2025

Verdiva Bio creates cutting-edge treatments that improve results for patients with obesity and cardiometabolic diseases.

Biotechnology · London$411.0M Series A
Just - Evotec Biologics
January 2026

Designing innovative technologies focused on accelerating global access to biotherapeutics.

Biopharma · SeattleGrant
Alumis
January 2026

Alumis is a precision medicine company focused on the discovery, development and treatment of autoimmune disorders.

Biotechnology · San Francisco$345.1M Post-IPO Equity
Synthekine
January 2023

Synthekine is a development stage biotherapeutics company focused on the engineering of novel specific and potent cytokine therapies.

Biotechnology · Menlo Park$100.0M Series C
Terns Pharmaceuticals
December 2025

Terns Pharmaceuticals develops small-molecule therapies for chronic diseases including cancer, metabolic disorders, and liver conditions.

Biotechnology · Foster City$650.0M Post-IPO Equity
Structure Therapeutics
December 2025

Structure Therapeutics specializes in the discovery and development of drugs against a type of targets called GPCR.

Biotechnology · South San Francisco$747.5M Post-IPO Equity
SciNeuro
December 2025

SciNeuro is a clinical-stage biotechnology company focused on developing groundbreaking therapies for neurodegenerative diseases.

Biopharma · Rockville$53.0M Venture - Series Unknown
Akura Medical
December 2025

Akura Medical is developing a next-generation thrombectomy device that aims to simplify thrombectomy through an easy-to-use.

Health Care · Los Gatos$53.0M Series C
Regor Therapeutics
December 2021

Regor Therapeutics is an international biotech company that focuses in the therapeutic areas of oncology, metabolic and autoimmune diseases.

Biotechnology · Boston$50.0M Venture - Series Unknown

Where Lilly Asia Ventures invests

Biotechnology22
Health Care16
Medical12
Pharmaceutical11
Therapeutics9
Life Science7

About Lilly Asia Ventures's portfolio

How many companies has Lilly Asia Ventures invested in?

Lilly Asia Ventures has invested in 102 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Lilly Asia Ventures invest in?

Lilly Asia Ventures's top investment sectors include Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics. The firm invests across 14 different industry categories.

What is Lilly Asia Ventures's largest investment?

Among tracked funding rounds, Structure Therapeutics received $747.5M in a Post-IPO Equity round. Lilly Asia Ventures's total known invested capital is $7.7B.

What is the average investment size for Lilly Asia Ventures?

Lilly Asia Ventures's average investment size is $95.6M across its portfolio of 102 companies.

What are Lilly Asia Ventures's most recent investments?

Recent Lilly Asia Ventures portfolio additions include Genesis Medtech, CinCor Pharma, Singlera Genomics, Legend Biotech, Tempest Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 102 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →